To the best of our knowledge, this was the first study addressing a central role of PDE10A in progressive pulmonary vascular remodeling, and we propose the inhibition of PDE10A as a novel therapeutic approach to the treatment of PAH. Here, PDE10A is linked to pulmonary arterial hypertension.